MorphoSys AG
XETRA:MOR
MorphoSys AG
XETRA:MOR
Price:
68.25 EUR
0.22%
Updated:
May 21, 2024
MorphoSys AG
Income from Continuing Operations
|
MorphoSys AG
Income from Continuing Operations Peer Comparison
Comparables:
BNTX
CVAC
IMTX
BIO
FYB
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
MorphoSys AG
XETRA:MOR
|
Income from Continuing Operations
-€456.3m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-50%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Income from Continuing Operations
€930.3m
|
CAGR 3-Years
296%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Income from Continuing Operations
-€260.2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Income from Continuing Operations
-€97m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-25%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Income from Continuing Operations
€156.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
18%
|
|
|
Formycon AG
XETRA:FYB
|
Income from Continuing Operations
€75.8m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
See Also
What is MorphoSys AG's Income from Continuing Operations?
Income from Continuing Operations
-456.3m
EUR
-456.3m
EUR
Based on the financial report for Mar 31, 2024, MorphoSys AG's Income from Continuing Operations amounts to -456.3m EUR.
What is MorphoSys AG's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-50%
-50%
Over the last year, the Income from Continuing Operations growth was -527%. The average annual Income from Continuing Operations growth rates for MorphoSys AG have been -37% over the past three years , -50% over the past five years .
You don't have any saved screeners yet
